Zobrazeno 1 - 10
of 763
pro vyhledávání: ''
Autor:
Michelle A Cai, Timothy J. Ley, Lukas D. Wartman, Sridhar Nonavinkere Srivatsan, Timothy P Rooney, Sai Mukund Ramakrishnan, Christopher A. Miller, Nichole M. Helton, Casey D.S. Katerndahl, Ryan B. Day, Olivia R S Rogers, Mieke Hoock
Publikováno v:
Blood
Most patients with acute promyelocytic leukemia (APL) can be cured with combined all-trans retinoic acid (ATRA) and arsenic trioxide therapy, which induces the destruction of PML-RARA, the initiating fusion protein for this disease. However, the unde
Autor:
Rachel Thijssen, Edward Chew, Sarah S. Gabriel, Brandon J. Aubrey, Ashish Bajel, Andrew W. Roberts, Andreas Strasser, Marie Schoumacher, David A. Stroud, Chris D. Riffkin, Claudia Bruedigam, Donia M Moujalled, Natasha S Anstee, Tirta Mario Djajawi, Veronique Litalien, Ruth M. Kluck, Lin Tai, Andrew H. Wei, Thomas David Morley, Zhen Xu, Giovanna Pomilio, Sarah T. Diepstraten, Sarah MacRaild, Axel Kallies, Christoffer Flensburg, Boris Reljic, Steven W. Lane, Maoshan Chen, Catherine Chang, Gemma L. Kelly, David C. S. Huang, Fiona C. Brown, Sébastien Banquet, Michael A. Dengler, Melissa X Shi, Ian J. Majewski
Publikováno v:
Blood. 137:2721-2735
Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targe
Autor:
Christoffer Flensburg, Piers Blombery, David C.S. Huang, Huaxian Ma, Giovanna Pomilio, Sarah MacRaild, Sanam Loghavi, Rachel Thijssen, Fiona C. Brown, Ian J. Majewski, Jessica M. Salmon, Ing Soo Tiong, Hagop M. Kantarjian, Adam Ivey, Xufeng Chen, Keyur P. Patel, Ioannis Aifantis, A. Quaglieri, Shaun Fleming, Courtney D. DiNardo, Zhen Xu, Andrew W. Roberts, Marina Konopleva, Nik Cummings, Qi Zhang, Andrew H. Wei, Steve Kornblau, Chong Chyn Chua, Christina Glytsou
Publikováno v:
Blood. 135:791-803
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based com
Autor:
Michael Andreeff, Marcela Gronda, Yoosu Na, Rose Hurren, Xiaoming Wang, Neil MacLean, Andrea Arruda, Sara Mirali, Hyeonjeong Kang, Dilshad H. Khan, Zoe Alaniz, Marina Konopleva, Li Zhang, Mark D. Minden, Yulia Jitkova, Jongbok Lee, Aaron D. Schimmer, Mingjing Xu
Publikováno v:
Blood
The combination of venetoclax and the hypomethylating agent azacytidine induces a high rate of complete responses in treatment-naïve older patients with acute myeloid leukemia (AML). Lee and colleagues elucidate a novel mechanism of action for the s
Autor:
Alexander E. Perl
Publikováno v:
Blood. 134:741-745
The natural history of FLT3-mutated AML is changing after the approval of midostaurin for frontline therapy and gilteritinib for relapsed or refractory patients. Recently reported, positive randomized trials of the drugs gilteritinib, quizartinib, an
Autor:
Philipp J. Hohensinner, Adelheid Panzenböck, Robert J. Parmer, Nagyung Baik, Kurt Huber, Johann Wojta, Walter S. Speidl, Gersina Rega-Kaun, Manfred Prager, Johanna Baumgartner, Christoph Kaun, Stefan Stojkovic, Svitlana Demyanets, Barbara Thaler, Ihor Huk, Lindsey A. Miles, Michael B. Fischer
Publikováno v:
Blood. 134:561-567
Membrane-bound plasmin is used by immune cells to degrade extracellular matrices, which facilitates migration. The plasminogen receptor Plg-RKT is expressed by immune cells, including monocytes and macrophages. Among monocytes and macrophages, distin
Autor:
Donald A. Simone, Sergey G. Khasabov, Megan L. Uhelski, Virginia S. Seybold, Kalpna Gupta, Iryna A. Khasabova
Publikováno v:
Blood. 133:1989-1998
Pain is a characteristic feature of sickle cell disease (SCD), 1 of the most common inherited diseases. Patients may experience acute painful crises as well as chronic pain. In the Berkley transgenic murine model of SCD, HbSS-BERK mice express only h
Autor:
Andreas Strasser, Grant Dewson, Lin Tai, Margs S. Brennan, Catherine Chang, Marco J Herold, Gemma L. Kelly, Guillaume Lessene
Publikováno v:
Blood. 132:1573-1583
Myeloid cell leukemia-1 (MCL-1) is a prosurvival B-cell lymphoma 2 (BCL-2) family member required for the sustained growth of many cancers. Recently, a highly specific MCL-1 inhibitor, S63845, showing sixfold higher affinity to human compared with mo
Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis
Autor:
Faris Ali, Edvinas Vaicikauskas, Robert E. Fleming, Yelena Ginzburg, Amaliris Guerra, Carla Casu, Maria Feola, Luke Mammen, Nermi L. Parrow, Yihang Li, Stefano Rivella, Princy Prasad
Publikováno v:
Blood
Transferrin, the major plasma iron-binding molecule, interacts with cell-surface receptors to deliver iron, modulates hepcidin expression, and regulates erythropoiesis. Transferrin binds and releases iron via either or both of 2 homologous lobes (N a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b34fe3622fad94013f80bc95278d43c2
https://europepmc.org/articles/PMC6839954/
https://europepmc.org/articles/PMC6839954/
Autor:
Deborah M. Stephens
Publikováno v:
Blood. 133:386-388
In this issue of Blood, Langerak et al report on the prognostic value of minimal residual disease (MRD) status in elderly patients with comorbid chronic lymphocytic leukemia (CLL) who were treated on the phase 3 CLL11 trial with chlorambucil plus rit